We trace our roots back to Dr Joel Margolis who escaped out of Poland as WWII was erupting in September 1939. Joel migrated to Australia with his family and read medicine at Melbourne University before becoming a preeminent researcher in the haematology field. Joel was the first person to develop a process to make FVIII AIDS free in early 1980’s. Joel invented the tangential flow Electrophoresis process as an alternative to NASA’s attempts to do biological separations in space.
Dr Perry Manusu, an Australian Veterinary, Surgeon and entrepreneur, who created the largest vet practice and vet pharmaceutical company, joined with Joel to develop this process which they called The Gradiflow. The first Gradiflow patent was lodged in 1984.
In 1985 John Manusu joined the company and helped take Gradipore public in May 1986. Tangential flow Electrophoresis as applied to plasma protein purification was spearheaded by Dr Hari Nair when he joined Gradipore in 1998 and developed the various applications of the Gradiflow including viral and prion removal.
By early 2002 there were some 50 patent families covering a number of aspects of the Gradiflow technology. In 2004 the 3 founders (Perry, Hari, John) rebuilt Gradipore and acquired Serologics, a US plasma collection business specialising in hyperimmune plasmas through FDA approved centres. They used this acquisition to refine the plasma fractionation process, particularly for hyperimmune products. By 2007 the company, then called Life Therapeutics, was the largest non-fractionator plasma collection business in the world, collecting normal, hyperimmune and bioterrorism plasmas. They agreed to sell the business to the Italian fractionator Kedrion. Having announced this agreement the founders retired, and the new Board sold the collection centers.
In the meantime, John and Hari setup another company called NuSep which developed an IVF application for the Gradiflow technology. A successful clinical study was completed in 2008. In 2010, NuSep was offered a small cGMP facility in Singapore and the company chose to reactivate the plasma separation technology. Hari further refined the fractionation process particularly around the disposable cartridge which enabled the processing of plasma collected from emerging economies.